Amgen, Inc. (AMGN)
439.26
-8.02
(-1.79%)
USD |
NASDAQ |
Oct 23, 16:00
441.99
+2.73
(+0.62%)
After-Hours: 20:00
Amgen Enterprise Value : 280.78B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 280.78B |
| October 22, 2026 | 285.11B |
| October 21, 2026 | 280.28B |
| October 20, 2026 | 280.61B |
| October 19, 2026 | 273.04B |
| October 16, 2026 | 277.12B |
| October 15, 2026 | 277.95B |
| October 14, 2026 | 273.67B |
| October 13, 2026 | 266.50B |
| October 12, 2026 | 269.05B |
| October 09, 2026 | 267.59B |
| October 08, 2026 | 263.58B |
| October 07, 2026 | 266.63B |
| October 06, 2026 | 260.96B |
| October 05, 2026 | 261.17B |
| October 02, 2026 | 261.20B |
| October 01, 2026 | 263.49B |
| September 30, 2026 | 271.18B |
| September 29, 2026 | 272.33B |
| September 28, 2026 | 269.36B |
| September 25, 2026 | 267.45B |
| September 24, 2026 | 262.82B |
| September 23, 2026 | 262.85B |
| September 22, 2026 | 265.09B |
| September 21, 2026 | 255.86B |
| Date | Value |
|---|---|
| September 18, 2026 | 251.80B |
| September 17, 2026 | 248.62B |
| September 16, 2026 | 246.77B |
| September 15, 2026 | 246.39B |
| September 14, 2026 | 249.55B |
| September 11, 2026 | 247.31B |
| September 10, 2026 | 250.08B |
| September 09, 2026 | 254.84B |
| September 08, 2026 | 255.86B |
| September 04, 2026 | 279.68B |
| September 03, 2026 | 283.41B |
| September 02, 2026 | 282.71B |
| September 01, 2026 | 280.16B |
| August 31, 2026 | 275.71B |
| August 28, 2026 | 277.08B |
| August 27, 2026 | 279.55B |
| August 26, 2026 | 281.36B |
| August 25, 2026 | 282.39B |
| August 24, 2026 | 283.25B |
| August 21, 2026 | 280.82B |
| August 20, 2026 | 277.79B |
| August 19, 2026 | 282.45B |
| August 18, 2026 | 273.22B |
| August 17, 2026 | 270.03B |
| August 14, 2026 | 267.78B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 214.93B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
| AbbVie, Inc. | 569.05B |
| Biogen, Inc. | 44.10B |
| Abbott Laboratories | 207.10B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.375B |
| Revenue (Quarterly) | 10.07B |
| Total Expenses (Quarterly) | 7.692B |
| EPS Diluted (Quarterly) | 4.366 |
| Gross Profit Margin (Quarterly) | 72.08% |
| Profit Margin (Quarterly) | 23.59% |
| Earnings Yield | 3.66% |
| Operating Earnings Yield | 5.33% |
| Normalized Earnings Yield | 4.016 |